Skip to content

Ardelyx ARDX Deferred royalty obligation

Deferred royalty obligation at other companies

Collegium Pharmaceutical, Inc. logo
Collegium Pharmaceutical, Inc.COLL
$121.63M+0.1%
Omeros logo
OmerosOMER
$141.93M-25.3%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$407.18M-12.7%
PVL
Palvella TherapeuticsPVLA
$19.8M+50.5%
BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
$40.32M+17.5%
Ultragenyx Pharmaceutical logo
Ultragenyx PharmaceuticalRARE
$1.13B+42.1%

Other financials

Income statement

See full
Revenue$94.5M+27.5%
Gross profit$89.7M+45.1%
Operating income-$32.8M+9.8%
Net income-$37.6M+8.6%
EPS (diluted)-$0.15+11.8%

Balance sheet

See full
Cash & equivalents$31.2M+1.3%
Total debt$208.3M+34.3%
Total equity$148.6M+2.0%
Total assets$504.5M+23.0%

Cash flow

See full
Operating cash flow-$32.2M+16.2%
CapEx$69.0K-78.8%
Free cash flow-$32.3M+16.7%

Valuation

See full
Market cap$1.53B+79.5%
Enterprise value$1.71B+74.8%
P/S3.6×+1.2×

Profitability

See full
Gross margin92.5%+7.9pp
Operating margin-25.4%
Net margin-13.6%
FCF margin-40.9%

Returns & leverage

See full
Return on equity-39.5%
Debt / equity1.4×+0.3×
Current ratio3.5×-0.6×

Where this comes from

Reported directly by Ardelyx in its filing.

Tagged under the XBRL concept ardx:DeferredTaxAssetsRoyaltyObligation.

The official record: Ardelyx’s 10-K, filed February 19, 2026, on SEC EDGAR. View the filing →

Ask your AI about Ardelyx's deferred royalty obligation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Ardelyx's deferred royalty obligation?
Ardelyx (ARDX) reported deferred royalty obligation of $6.5M in Q4 2025.
What is the long-term trend for Ardelyx's deferred royalty obligation?
Over 3 years (2022 to 2025), Ardelyx's deferred royalty obligation has grown at a 36.1% compound annual growth rate (CAGR), from $2.58M to $6.5M.
What does deferred royalty obligation mean?
The liability representing future royalty payments owed to third parties based on product sales, often arising from in-licensing agreements. This reflects the long-term cost of accessing intellectual property or proprietary technology. Managing this obligation is crucial for assessing the long-term margin profile of the company's commercialized products.